Sucunamostat | 1802888-04-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Sucunamostat
• 英文别名: (2S)-2-[[2-[(3S)-6-[4-(diaminomethylideneamino)benzoyl]oxy-2,3-dihydro-1-benzofuran-3-yl]acetyl]amino]butanedioic acid
• CAS: 1802888-04-5
• 化学式: C₂₂H₂₂N₄O₈
• 分子量: 470.4
• InChiKey: PUZUTMLAAWVCCV-WBMJQRKESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  204
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• FUSED HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150225361A1

  公开（公告）日：2015-08-13

  A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

  提供了一种具有肠酶抑制作用的融合杂环化合物，并将该化合物用作治疗或预防肥胖症、糖尿病等疾病的药物。具体而言，提供了以下式（I）所表示的化合物：其中每个符号如本文所定义，或其盐，并将该化合物用作治疗或预防肥胖症、糖尿病等疾病的药物。
• DOUBLE-HEADED PROTEASE INHIBITOR
  申请人：UBE Industries, Ltd.

  公开号：EP3705471A1

  公开（公告）日：2020-09-09

  The present invention provides a compound that is highly safe and useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical composition containing the compound, a method for producing the compound, and the like. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein: A1 and A2 each independently represent an inhibitor residue having at least one activity selected from an enteropeptidase inhibitory activity and a trypsin inhibitory activity; and Z represents a spacer that links A1 to A2] or a pharmaceutically acceptable salt thereof.

  本发明提供了一种在预防、缓解和/或治疗涉及肠肽酶抑制和/或胰蛋白酶抑制的各种疾病方面高度安全且有用的化合物、一种含有该化合物的药物组合物、一种生产该化合物的方法等。具体而言，本发明提供了由以下通式（I）代表的化合物： 其中A1和A2各自独立地代表具有至少一种选自肠肽酶抑制活性和胰蛋白酶抑制活性的抑制剂残基；Z代表连接A1和A2的间隔物]或其药学上可接受的盐。
• DIHYDROBENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF DIABETES AND OBESITY
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3105213B1

  公开（公告）日：2019-01-09
• US9346776B2
  申请人：——

  公开号：US9346776B2

  公开（公告）日：2016-05-24
• US9969705B2
  申请人：——

  公开号：US9969705B2

  公开（公告）日：2018-05-15